Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy : final results of the randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group